Ablation of ferroptosis regulator glutathione peroxidase 4 in forebrain neurons promotes cognitive impairment and neurodegeneration

Redox Biology

Volumn 12, Issue , 2017, Pages 8-17

  Hambright, William Sealy ^a   Fonseca, Rene Solano ^a   Chen, Liuji ^a   Na, Ren ^a   Ran, Qitao ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

Alzheimer's disease; Cognitive impairment; Ferroptosis; Glutathione peroxidase 4; Neurodegeneration; Transgenic mice

Indexed keywords

ALPHA TOCOPHEROL; BIOLOGICAL MARKER; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOLIPID HYDROPEROXIDE GLUTATHIONE PEROXIDASE; TAMOXIFEN; GLUTATHIONE PEROXIDASE; GLUTATHIONE PEROXIDASE 4, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; BRAIN CORTEX; BRAIN NERVE CELL; CELL DEATH; COGNITIVE DEFECT; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; FERROPTOSIS; FOREBRAIN; HIPPOCAMPUS; LEARNING DISORDER; LIPID PEROXIDATION; MALE; MEMORY DISORDER; MORRIS WATER MAZE TEST; MOUSE; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; NUTRITIONAL DEFICIENCY; SPATIAL LEARNING; ANIMAL; CHEMICALLY INDUCED; CYTOLOGY; DEGENERATIVE DISEASE; DISEASE MODEL; GENE KNOCKOUT; GENETICS; MAZE TEST; METABOLISM; NERVE CELL; OXIDATION REDUCTION REACTION;

ANIMALS; CELL DEATH; COGNITIVE DYSFUNCTION; DISEASE MODELS, ANIMAL; GENE KNOCKOUT TECHNIQUES; GLUTATHIONE PEROXIDASE; LIPID PEROXIDATION; MAZE LEARNING; MICE; NEURODEGENERATIVE DISEASES; NEURONS; OXIDATION-REDUCTION; PROSENCEPHALON; TAMOXIFEN;

EID: 85012900626     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2017.01.021     Document Type: Article

References (31)

1. [1] Cotman, C.W., Anderson, A.J., A potential role for apoptosis in neurodegeneration and Alzheimer's disease. Mol. Neurobiol. 10:1 (1995), 19–45.
2. [2] Mattson, M.P., Neuronal life-and-death signaling, apoptosis, and neurodegenerative disorders. Antioxid. Redox Signal. 8:11–12 (2006), 1997–2006.
3. [3] Khandelwal, P.J., Herman, A.M., Moussa, C.E., Inflammation in the early stages of neurodegenerative pathology. J. Neuroimmunol. 238:1–2 (2011), 1–11.
4. [4] Wang, X., Wang, W., Li, L., Perry, G., Lee, H.G., Zhu, X., Oxidative stress and mitochondrial dysfunction in Alzheimer's disease. Biochim. Biophys. Acta, 2013.
5. [5] Gordon, P.H., Moore, D.H., Miller, R.G., Florence, J.M., Verheijde, J.L., Doorish, C., Hilton, J.F., Spitalny, G.M., MacArthur, R.B., Mitsumoto, H., et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol. 6:12 (2007), 1045–1053.
6. [6] PRECEPT investigators of the Parkinson's Study Group, Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology 69:15 (2007), 1480–1490.
7. [7] Markesbery, W.R., Carney, J.M., Oxidative alterations in Alzheimer's disease. Brain Pathol. 9:1 (1999), 133–146.
8. [8] Butterfield, D.A., Lauderback, C.M., Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radic. Biol. Med. 32:11 (2002), 1050–1060.
9. [9] Pratico, D., Sung, S., Lipid peroxidation and oxidative imbalance: early functional events in Alzheimer's disease. J. Alzheimers Dis. 6:2 (2004), 171–175.
10. [10] Castellani, R.J., Moreira, P.I., Liu, G., Dobson, J., Perry, G., Smith, M.A., Zhu, X., Iron: the redox-active center of oxidative stress in Alzheimer disease. Neurochem. Res. 32:10 (2007), 1640–1645.
11. [11] Dixon, S.J., Lemberg, K.M., Lamprecht, M.R., Skouta, R., Zaitsev, E.M., Gleason, C.E., Patel, D.N., Bauer, A.J., Cantley, A.M., Yang, W.S., et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149:5 (2012), 1060–1072.
12. [12] Linkermann, A., Skouta, R., Himmerkus, N., Mulay, S.R., Dewitz, C., De, Z.F., Prokai, A., Zuchtriegel, G., Krombach, F., Welz, P.S., et al. Synchronized renal tubular cell death involves ferroptosis. Proc. Natl. Acad. Sci. USA 111 (2014), 16836–16841.
13. [13] Friedmann Angeli, J.P., Schneider, M., Proneth, B., Tyurina, Y.Y., Tyurin, V.A., Hammond, V.J., Herbach, N., Aichler, M., Walch, A., Eggenhofer, E., et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat. Cell Biol. 16:12 (2014), 1180–1191.
14. [14] Heneka, M.T., O'Banion, M.K., Terwel, D., Kummer, M.P., Neuroinflammatory processes in Alzheimer's disease. J. Neural Transm. 117:8 (2010), 919–947.
15. [15] Yang, W.S., Stockwell, B.R., Ferroptosis: death by lipid peroxidation. Trends Cell Biol. 26:3 (2016), 165–176.
16. [16] Girotti, A.W., Lipid hydroperoxide generation, turnover, and effector action in biological systems. J. Lipid Res. 39:8 (1998), 1529–1542.
17. [17] Yang, W.S., SriRamaratnam, R., Welsch, M.E., Shimada, K., Skouta, R., Viswanathan, V.S., Cheah, J.H., Clemons, P.A., Shamji, A.F., Clish, C.B., et al. Regulation of ferroptotic cancer cell death by GPX4. Cell 156:1–2 (2014), 317–331.
18. [18] Matsushita, M., Freigang, S., Schneider, C., Conrad, M., Bornkamm, G.W., Kopf, M., T cell lipid peroxidation induces ferroptosis and prevents immunity to infection. J. Exp. Med. 212:4 (2015), 555–568.
19. [19] Chen, L., Hambright, W.S., Na, R., Ran, Q., Ablation of the ferroptosis inhibitor glutathione peroxidase 4 in neurons results in rapid motor neuron degeneration and paralysis. J. Biol. Chem. 290:47 (2015), 28097–28106.
20. [20] Yoo, S.E., Chen, L., Na, R., Liu, Y., Rios, C., Van, R.H., Richardson, A., Ran, Q., Gpx4 ablation in adult mice results in a lethal phenotype accompanied by neuronal loss in brain. Free Radic. Biol. Med. 52:9 (2012), 1820–1827.
21. [21] Madisen, L., Zwingman, T.A., Sunkin, S.M., Oh, S.W., Zariwala, H.A., Gu, H., Ng, L.L., Palmiter, R.D., Hawrylycz, M.J., Jones, A.R., et al. A robust and high-throughput cre reporting and characterization system for the whole mouse brain. Nat. Neurosci. 13:1 (2010), 133–140.
22. [22] Chen, L., Na, R., Boldt, E., Ran, Q., NLRP3 inflammasome activation by mitochondrial reactive oxygen species plays a key role in long-term cognitive impairment induced by paraquat exposure. Neurobiol. Aging 36:9 (2015), 2533–2543.
23. [23] Schmued, L.C., Albertson, C., Slikker, W. Jr., Fluoro-Jade: a novel fluorochrome for the sensitive and reliable histochemical localization of neuronal degeneration. Brain Res. 751:1 (1997), 37–46.
24. [24] Wang, X., Michaelis, E.K., Selective neuronal vulnerability to oxidative stress in the brain. Front. Aging Neurosci., 2, 2010, 12.
25. [25] Xie, Y., Hou, W., Song, X., Yu, Y., Huang, J., Sun, X., Kang, R., Tang, D., Ferroptosis: process and function. Cell Death Differ. 23:3 (2016), 369–379.
26. [26] Yagoda, N., von, R.M., Zaganjor, E., Bauer, A.J., Yang, W.S., Fridman, D.J., Wolpaw, A.J., Smukste, I., Peltier, J.M., Boniface, J.J., et al. RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature 447:7146 (2007), 864–868.
27. [27] Coyle, J.T., Puttfarcken, P., Oxidative stress, glutamate, and neurodegenerative disorders. Science 262:5134 (1993), 689–695.
28. [28] Do, V.B., Gouel, F., Jonneaux, A., Timmerman, K., Gele, P., Petrault, M., Bastide, M., Laloux, C., Moreau, C., Bordet, R., et al. Ferroptosis, a newly characterized form of cell death in Parkinson's disease that is regulated by PKC. Neurobiol. Dis., 2016.
29. [29] Ran, Q., Gu, M., Van Remmen, H., Strong, R., Roberts, J.L., Richardson, A., Glutathione peroxidase 4 protects cortical neurons from oxidative injury and amyloid toxicity. J. Neurosci. Res. 84:1 (2006), 202–208.
30. [30] Yoo, M.H., Gu, X., Xu, X.M., Kim, J.Y., Carlson, B.A., Patterson, A.D., Cai, H., Gladyshev, V.N., Hatfield, D.L., Delineating the role of glutathione peroxidase 4 in protecting cells against lipid hydroperoxide damage and in Alzheimer's disease. Antioxid. Redox Signal. 12:7 (2010), 819–827.
31. [31] Hofmans, S., Vanden Berghe, T., Devisscher, L., Hassannia, B., Lyssens, S., Joossens, J., Van Der Veken, P., Vandenabeele, P., Augustyns, K., Novel ferroptosis inhibitors with improved potency and ADME properties. J. Med. Chem. 59:5 (2016), 2041–2053.